AI & Machine Learning

Vocodia Holdings is acquiring PrivacyPal.ai to combat 'Shadow AI' and solve the 'Fidelity Paradox,' aiming to secure AI use for businesses and individuals.

With $82M in funding and novel gene insertion technology, Averna Therapeutics is poised to make waves at the pivotal J.P. Morgan Healthcare Conference.

With record revenue and a bold AI strategy, Opera heads to a key investor conference. Can its 'agentic' browsers redefine the web and win market share?

Biocytogen and Acepodia are expanding their partnership to create next-gen ADCs with two targets and two warheads, aiming to defeat drug-resistant cancers.

Facing complex 2025 tax changes? H&R Block is offering new DIY clients a free professional review, blending digital convenience with expert assurance.

An expanded partnership aims to create next-gen cancer therapies by combining bispecific antibodies with two distinct drugs to overcome tumor resistance.

The biotech firm lands a major private placement, extending its cash runway to 2028 and signaling strong investor confidence in its novel drug platform.

Major insurers now cover advanced AI plaque analysis, paving the way for personalized heart attack prevention and a new standard of cardiovascular care.

The biotech firm now expects Phase 2 results in Q3 2026, accelerating hope for new CNS treatments and signaling strong operational momentum to investors.

With a new board chair, regulatory backing, and an AI platform, GC Therapeutics is targeting MS and diabetes with next-generation cell therapies.

Predis.ai's new AI promises to slash video ad costs and production time, empowering small businesses and challenging traditional marketing workflows.

Brookfield Asset Management renews its major share buyback plan, a strategic signal of confidence aimed at boosting shareholder value amid market shifts.

Upbound Group's new CEO and CFO head to the prestigious ICR Conference. Investors await insights on growth, credit trends, and financial inclusion strategy.

A new partnership integrates Lilly's powerful TuneLab AI into Schrödinger's LiveDesign, promising to accelerate R&D with a novel privacy-first approach.

Sanofi deepens its AI partnership with CytoReason in a $16M deal, signaling a major shift in using predictive models to accelerate immunology breakthroughs.

Ocugen heads to a top investor conference with a bold plan for its gene-agnostic therapy, aiming to treat blindness and secure its future in a crowded market.

The institutional crypto exchange reported a sharp decline in spot trading for December, but a massive surge in options volume points to a maturing market.

Facing a Nasdaq delisting notice, Chinese office provider Ucommune plans drastic measures amid dire financials and a saturated real estate market.

The acquisition combines autonomous ship platforms with advanced AI, creating an end-to-end solution aimed at dominating the future of maritime defense.

A new platform, ConvoGPT OS, has been unveiled with a bold mission: to eliminate human sales jobs, not just assist them, raising major questions for the future of work.